



How Paediatric Research Networks can help drug development

Mark Turner







Why networks?

Significant increase in trials and participants

Delays are now significant

...Networks can address all of these issues





Why networks?

Most work to optimise trial conduct in children has been done already

In many cases there is good practice to apply

If you are having to design solutions to clinical trial challenges then you are not using your time effectively

Your KOLs may not have expertise in trial conduct or regulatory issues relevant to PIP / PSP design

... Networks can address all of these issues





Support advancement of knowledge by facilitating the diffusion of:

Information

Studies

Generic resources

Expertise

- Added value
- Avoid reinventing the wheel

Data

- Databases
- Links to epidemiology resources





Support advancement of knowledge by facilitating the diffusion of:

Information

Studies

Generic resources

Expertise

- Added value
- Avoid reinventing the wheel


Data

- Databases
- Links to epidemiology resources

Few networks can do all of these but it is worth asking if they can


















Participant Experience

Rights / Ethics

"No research for us without us"

Operational

Therapeutic need

Study design / Acceptability

Documentation





Participant Experience

Rights / Ethics

"No research for us without us"

Operational

Therapeutic need

Study design / Acceptability

Documentation







Young People's Advisory Groups

Facilitated groups

Awareness of trial processes

Comment on


- Therapeutic need
- Outcomes
- Assessments
- Formulations
- Trial documentation



http://www.icanresearch.org
































How to use networks

Potential entry points:

Identify therapeutic need

Due diligence


Pre-IND

Develop PIP

Develop protocol

Implement protocol

Rescue protocol







How **not** to use networks

Potential entry points:

Identify therapeutic need

Due diligence


Pre-IND

Develop PIP

Develop protocol


Implement protocol

Rescue protocol














Trial Implementation








Trial Implementation


CORE BUSINESS FOR MANY NETWORKS







Trial Implementation





How can (some) networks help study design?

Real-world data about incidence / feasibility

Identify similarities / differences between adult and children

Using adult data to minimise studies in children

See extrapolation concept paper

Standard of care

Which assessments / outcomes are feasible





How can (some) networks help study design?

Real-world data about incidence / feasibility

Identify similarities / differences between adult and children

Using adult data to minimise studies in children

See extrapolation concept paper

Standard of care


Which assessments / outcomes are feasible

Direct help or signposting





Trial Implementation







Mutual learning

Not all networks can do all these tasks

Nevertheless, they can contribute to some of these activities

We all need to learn from each other: networks and companies can learn from each other

EnprEMA and most networks are not funded. The networks are often voluntary and try to help when they can

You get what you pay for (most of the time)





Networks will improve

IMI2 potential call



Topic: Creation of a pan-European Paediatric Clinical Trials Network



How to use networks

Contact early

Single contact point in the network and your organization

"Business Relationship Manager"

Develop horizontal links within your organization so that the corporate memory is enriched by working with networks





Thank you for your attention

Further information

European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

Follow us on ***** @EMA_News**